Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastasesResearch in context
Eftychia Chatziioannou,
Jana Roßner,
Thazin New Aung,
David L. Rimm,
Heike Niessner,
Ulrike Keim,
Lina Maria Serna-Higuita,
Irina Bonzheim,
Luis Kuhn Cuellar,
Dana Westphal,
Julian Steininger,
Friedegund Meier,
Oltin Tiberiu Pop,
Stephan Forchhammer,
Lukas Flatz,
Thomas Eigentler,
Claus Garbe,
Martin Röcken,
Teresa Amaral,
Tobias Sinnberg
Affiliations
Eftychia Chatziioannou
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany
Jana Roßner
Department of Dermatology, University of Heidelberg, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany
Thazin New Aung
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
David L. Rimm
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA
Heike Niessner
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany
Ulrike Keim
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany
Lina Maria Serna-Higuita
Department of Clinical Epidemiology and Applied Biostatistics, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany
Irina Bonzheim
Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany
Luis Kuhn Cuellar
Quantitative Biology Center (QBiC), University of Tübingen, Tübingen, Germany
Dana Westphal
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany
Julian Steininger
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany
Friedegund Meier
Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Skin Cancer Center at the University Cancer Center and National Center for Tumor Diseases, Technical University Dresden, 01307 Dresden, Germany
Oltin Tiberiu Pop
Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Stephan Forchhammer
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany
Lukas Flatz
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Thomas Eigentler
Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Claus Garbe
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany
Martin Röcken
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany
Teresa Amaral
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany
Tobias Sinnberg
Department of Dermatology, University of Tübingen, Liebermeisterstr. 25, 72076 Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Corresponding author. Liebermeisterstr. 25, 72076 Tübingen, Germany.
Summary: Background: Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma. Methods: We included stage I to IV cutaneous melanoma patients and used hematoxylin-eosin-stained slides for TIL analysis. We assessed eTILs as a continuous and categorical variable using the published cut-off of 16.6% and applied Cox regression models to evaluate associations of eTILs with relapse-free, distant metastasis-free, and overall survival. We compared eTILs of the primaries with matched metastasis. Moreover, we assessed the predictive relevance of eTILs in therapy-naïve metastases according to the first-line therapy. Findings: We analysed 321 primary cutaneous melanomas and 191 metastatic samples. In simple Cox regression, tumour thickness (p 12.2% was associated with longer progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients treated with anti-PD-1-based immunotherapy. In multiple Cox regression, lactate dehydrogenase (p < 0.0001) and eTILs ≤12.2% (p = 0.0130) were significantly associated with unfavourable melanoma-specific survival. Interpretation: Assessment of TILs is prognostic in primary melanoma samples, and the eTILs complements staging. In therapy-naïve metastases, eTILs ≤12.2% is predictive of unfavourable survival outcomes in patients receiving anti-PD-1-based therapy. Funding: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.